These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 8646793)

  • 1. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
    Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
    Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M; Jensen PB
    Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin.
    Holm B; Jensen PB; Sehested M; Hansen HH
    Cancer Chemother Pharmacol; 1994; 34(6):503-8. PubMed ID: 7923561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
    Hofland KF; Thougaard AV; Dejligbjerg M; Jensen LH; Kristjansen PE; Rengtved P; Sehested M; Jensen PB
    Clin Cancer Res; 2005 Sep; 11(18):6722-9. PubMed ID: 16166453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.
    Jensen PB; Sehested M
    Biochem Pharmacol; 1997 Oct; 54(7):755-9. PubMed ID: 9353129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
    van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
    Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).
    Sehested M; Jensen PB; Sørensen BS; Holm B; Friche E; Demant EJ
    Biochem Pharmacol; 1993 Aug; 46(3):389-93. PubMed ID: 8394080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
    Tanabe K; Ikegami Y; Ishida R; Andoh T
    Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
    Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
    Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.